

Table S3. Immune history of patients after solid-organ transplantation with focus on BoDV-1 ELISpot outliers (upon stimulation with BoDV-1 N peptides).

patients after solid-organ transplantation	solid-organ transplantation	current immuno-suppressive medication	induction at time of transplantation	ABO-incompatibility	time since transplantation [years]	history of organ rejection	basic medical condition leading to nephropathy
outlier 1 (BoDV-1 ELISpot N)	kidney	MMF (360 mg/d) tacrolimus	no	no	9	unknown	hypertensive nephropathy
outlier 2 (BoDV-1 ELISpot N)	kidney	MMF (500 mg/d) everolimus	no	no	12	unknown	focal segmental glomerulosclerosis
outlier 3 (BoDV-1 ELISpot N)	kidney	MMF (1080 mg/d) tacrolimus	basiliximab	no	5	no	unknown
cohort (n = 27)	kidney: 93% kidney + pancreas: 7%	MMF: 85% (dosage 360-2000 mg/d) tacrolimus: 89% glucocorticoids: 33% others: 7%	yes: 33% no: 67%	yes: 15% no: 85%	median: 7 range: 1-23	yes: 19% no: 30% unknown: 52%	

MMF: mycophenolate mofetil.